Lu, W.; Sun, J.; Jing, Y.; Xu, J.; Huang, C.; Deng, Y.; Tian, P.; Li, Y.
Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with EGFR G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review. Curr. Oncol. 2025, 32, 201.
https://doi.org/10.3390/curroncol32040201
AMA Style
Lu W, Sun J, Jing Y, Xu J, Huang C, Deng Y, Tian P, Li Y.
Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with EGFR G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review. Current Oncology. 2025; 32(4):201.
https://doi.org/10.3390/curroncol32040201
Chicago/Turabian Style
Lu, Wenting, Jiayi Sun, Yawan Jing, Jing Xu, Chengming Huang, Yi Deng, Panwen Tian, and Yalun Li.
2025. "Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with EGFR G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review" Current Oncology 32, no. 4: 201.
https://doi.org/10.3390/curroncol32040201
APA Style
Lu, W., Sun, J., Jing, Y., Xu, J., Huang, C., Deng, Y., Tian, P., & Li, Y.
(2025). Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with EGFR G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review. Current Oncology, 32(4), 201.
https://doi.org/10.3390/curroncol32040201
